MENU

Fox Chase Cancer Center News

March 16, 2022

Researchers Identify Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma

PHILADELPHIA (March 16, 2022)—Researchers from Fox Chase Cancer Center have published an analysis of strategies for treating retroperitoneal soft tissue sarcoma (RPS), a form of cancer that has historically been understudied due to its rarity.

March 15, 2022

Camille Ragin Named Associate Director of Diversity, Equity, and Inclusion at Fox Chase Cancer Center

PHILADELPHIA (March 15, 2022)—Fox Chase Cancer Center has announced the appointment of Camille Ragin, PhD, MPH, as Associate Director of Diversity, Equity, and Inclusion (DEI).

March 15, 2022

Fox Chase Cancer Center Welcomes Amy M. Whitaker, PhD

PHILADELPHIA (March 15, 2022) – Fox Chase Cancer Center is pleased to announce the hiring of Amy M. Whitaker, PhD, who will join the Molecular Therapeutics research program and the Cancer Epigenetics Institute as an assistant professor.

March 2, 2022

Shannon Lynch Receives Real-World Data Impact Award from the American Cancer Society and Flatiron Health

PHILADELPHIA (March 2, 2022)—Shannon Lynch, PhD, MPH, assistant professor in the Cancer Prevention and Control research program at Fox Chase Cancer Center, has received the American Cancer Society (ACS) and Flatiron Health’s 2021 Real-World Data Impact Award. 

March 1, 2022

Suzanne M. Miller, PhD, Awarded Prevent Cancer Foundation Grant Focused on Cervical Cancer Disparities

PHILADELPHIA (March 1, 2022)—Fox Chase Cancer Center’s Suzanne M. Miller, PhD, a professor in the Cancer Prevention and Control research program, has received a two-year research grant from the Prevent Cancer Foundation to support a project designed to test whether text messaging can effectively reduce urban cervical cancer disparities.

February 25, 2022

Fox Chase Researchers Show Link Between Gene Defects and Tumor Mutation Burden in Head and Neck Cancer Subgroups

PHILADELPHIA (February 25, 2022)—In a study published in the prestigious journal Clinical Cancer Research, Fox Chase Cancer Center researchers show that specific categories of TP53 gene mutations are more likely to associate with CDKN2A gene mutations or high tumor mutation burden in some cases of head and neck cancer.

February 24, 2022

Newly Identified Fusion Gene Could Help Diagnose Rare Sarcoma

PHILADELPHIA (February 24, 2022)—Extraskeletal myxoid chondrosarcoma is a rare soft-tissue cancer that can be misdiagnosed. Now researchers at Fox Chase Cancer Center have identified a fusion gene that can help pathologists positively identify these tumors.

February 24, 2022

Fox Chase Cancer Center’s John Karanicolas Awarded University City Science Center Grant

PHILADELPHIA (February 24, 2022)—John Karanicolas, PhD, co-leader of the Molecular Therapeutics research program at Fox Chase Cancer Center, has been awarded a $200,000 grant as part of the University City Science Center’s QED Proof-of-Concept Program. The grant will fund research into developing antibodies that could be activated selectively in a tumor by a small molecule.

Pages

Connect with Fox Chase